Boundless Bio
are detected broadly across different cancer types but not in normal tissue or blood | Boundless Bio
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2024
Slide
16 of 51
Related slides by other companies
Kymera
Investor Day
December 2021
tissue selective degradation drives increase of therapeutic index | Kymera
AstraZeneca
Results
November 2024
top i blood cancers top | AstraZeneca
AstraZeneca
Investor Day
January 2022
are the next pillar for in oncology | AstraZeneca
AstraZeneca
Results
November 2024
blood cancers | AstraZeneca
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights